AbbVie (ABBV) Stock
Fundamentals
Recent news

Biotech Deal Week: Lilly, Novo And Novartis Pay Up For Platforms, Not Pipelines
Biotech Deal Week: Lilly, Novo And Novartis Pay Up For Platforms, Not Pipelines
ABBV

AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?
ABBV

US FDA approves AbbVie's drug for Parkinson's disease
US FDA approves AbbVie's drug for Parkinson's disease
ABBV

AbbVie vs. Pfizer: Which Healthcare Stock Makes Your Portfolio Healthier in 2026?
AbbVie vs. Pfizer: Which Healthcare Stock Makes Your Portfolio Healthier in 2026?
ABBV
Technicals
Analyst Ratings
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $3.71 for this quarter. The company has not yet shared when it is announcing earnings.
% positive news of 10 articles
published over the past 14 days
Latest news

Biotech Deal Week: Lilly, Novo And Novartis Pay Up For Platforms, Not Pipelines
Biotech Deal Week: Lilly, Novo And Novartis Pay Up For Platforms, Not Pipelines
ABBV

AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?
ABBV

US FDA approves AbbVie's drug for Parkinson's disease
US FDA approves AbbVie's drug for Parkinson's disease
ABBV

AbbVie vs. Pfizer: Which Healthcare Stock Makes Your Portfolio Healthier in 2026?
AbbVie vs. Pfizer: Which Healthcare Stock Makes Your Portfolio Healthier in 2026?
ABBV

ABBV vs. JNJ: One of These Dividend Aristocrats Will Crush the Other Over the Next Decade
ABBV vs. JNJ: One of These Dividend Aristocrats Will Crush the Other Over the Next Decade
ABBV

AbbVie vs. Novo Nordisk: Which Drug Giant Stock Is a Better Buy in 2026?
AbbVie vs. Novo Nordisk: Which Drug Giant Stock Is a Better Buy in 2026?
ABBV

AbbVie vs. Eli Lilly: Which Star Pharma Stock Is a Better Buy in 2026?
AbbVie vs. Eli Lilly: Which Star Pharma Stock Is a Better Buy in 2026?
ABBV

Pfizer or AbbVie: Which Big Pharma Stock Is the Better Pick?
Pfizer or AbbVie: Which Big Pharma Stock Is the Better Pick?
ABBV

Beyond Imbruvica: Can AbbVie Rebuild Its Oncology Portfolio?
Beyond Imbruvica: Can AbbVie Rebuild Its Oncology Portfolio?
ABBV

Prediction: Here's What $10,000 Invested in AbbVie Stock With Dividends Reinvested Could Be Worth in a Decade
Prediction: Here's What $10,000 Invested in AbbVie Stock With Dividends Reinvested Could Be Worth in a Decade
ABBV
About AbbVie
AbbVie, Inc. is a research-based biopharmaceutical company. It engages in the discovery, development, manufacture and sale of a broad line of proprietary pharmaceutical products. The company focused on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C and human immunodeficiency virus; neurological disorders, such as Parkinson's disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis; as well as other serious health conditions.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Scott T. Reents | Executive VP & CFO | 1967 |
| Dr. Azita Saleki Ph.D. | Executive VP & COO | 1963 |
| Dr. Roopal B. Thakkar M.D. | Executive VP of Research & Development and Chief Scientific Officer | 1972 |
| Mr. Jeffrey Ryan Stewart | Executive VP & Chief Commercial Officer | 1969 |
| Ms. Linda Ray | Senior VP & Chief Information Officer | — |
| Ms. Elizabeth Shea | Senior Vice President of Investor Relations | — |
| Mr. Perry C. Siatis | Executive VP, General Counsel & Secretary | 1975 |
| Mr. Demetris D. Crum | Executive VP & Chief Human Resources Officer | 1981 |
| Mr. Wulff-Erik von Borcke | Senior VP & President of Oncology | — |
| Dr. Nicholas J. Donoghoe M.D. | Executive VP and Chief Business & Strategy Officer | 1981 |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Solvency
Technicals
What the experts say
20 Wall Street Analyst Ratings
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -0.9 | +5.1 | +0.4 | +16.8 | ||||||||
| 2022 | +1.1 | +7.9 | +9.8 | -9.7 | -0.3 | +4.9 | -6.7 | -4.1 | -3.1 | +5.8 | +9.7 | -0.0 |
| 2023 | -9.0 | +5.0 | +2.6 | -5.8 | -10.2 | +1.0 | +10.8 | -1.1 | +0.6 | -4.8 | -0.1 | +8.1 |
| 2024 | +2.9 | +5.0 | +1.8 | -10.0 | -0.3 | +7.1 | +8.8 | +3.5 | -0.1 | +3.5 | -10.1 | -2.2 |
| 2025 | +2.5 | +9.9 | -0.9 | -5.4 | -3.7 | -0.7 | -0.5 | +7.8 | +9.3 | -10.8 | +7.4 | +1.5 |
| 2026 | -2.7 | +2.9 | -7.2 | -1.7 | +5.4 | +18.2 | -0.0 | +4.6 | +1.7 |



